Literature DB >> 20086109

Epidemiologic factors associated with seropositivity to human papillomavirus type 16 and 18 virus-like particles and risk of subsequent infection in men.

Beibei Lu1, Michael E Hagensee, Ji-Hyun Lee, Yougui Wu, Heather G Stockwell, Carrie M Nielson, Martha Abrahamsen, Mary Papenfuss, Robin B Harris, Anna R Giuliano.   

Abstract

Our understanding of humoral response to human papillomavirus (HPV) infection has been mainly derived from studies in women. The role of serum antibodies in the natural history of HPV in men has yet to be investigated. Data from 285 male participants of a natural history study were used to determine the epidemiologic factors associated with HPV 16/18 seropositivity and explore the role of HPV 16 and 18 serum antibodies in subsequent HPV infections. Serum antibodies were detected by use of HPV 16- and 18 virus-like particles enzyme-linked immunoassay. Logistic regression and Generalized Estimating Equation was used for the evaluation of risk factors. The risk of subsequent HPV infection by baseline antibody status was assessed by incidence rate ratio and its confidence intervals. Men ages 36 to 44 years compared with men ages 18 to 25 years were four times more likely to be seropositive to HPV 16/18. In addition, being divorced, separated, or widowed; being a former smoker; and having sex with men was positively and independently associated with HPV 16/18 seropositivity. Our findings on the potential role of HPV 16 or 18 serum antibodies in subsequent infection were inconclusive. Large prospective studies are warranted to adequately address questions on the role of natural immunity in the natural history of HPV infections in men.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20086109     DOI: 10.1158/1055-9965.EPI-09-0790

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  17 in total

1.  Bias Due to Correlation Between Times-at-Risk for Infection in Epidemiologic Studies Measuring Biological Interactions Between Sexually Transmitted Infections: A Case Study Using Human Papillomavirus Type Interactions.

Authors:  Talía Malagón; Philippe Lemieux-Mellouki; Jean-François Laprise; Marc Brisson
Journal:  Am J Epidemiol       Date:  2016-12-07       Impact factor: 4.897

2.  Serum antibody response following genital {alpha}9 human papillomavirus infection in young men.

Authors:  Zoe R Edelstein; Joseph J Carter; Ruchi Garg; Rachel L Winer; Qinghua Feng; Denise A Galloway; Laura A Koutsky
Journal:  J Infect Dis       Date:  2011-07-15       Impact factor: 5.226

Review 3.  Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review.

Authors:  Sarah M Tiggelaar; Margaret J Lin; Raphael P Viscidi; Jia Ji; Jennifer S Smith
Journal:  J Adolesc Health       Date:  2012-02       Impact factor: 5.012

4.  HPV vaccine and adolescent males.

Authors:  Paul L Reiter; Annie-Laurie McRee; Jessica A Kadis; Noel T Brewer
Journal:  Vaccine       Date:  2011-06-23       Impact factor: 3.641

5.  Gender and age-specific seroprevalence of human papillomavirus 16 and 18 in general population in Tehran, Iran.

Authors:  Arezoo Aghakhani; Setareh Mamishi; Shahram Sabeti; Farahnaz Bidari-Zerehpoosh; Mohammad Banifazl; Anahita Bavand; Amitis Ramezani
Journal:  Med Microbiol Immunol       Date:  2016-11-17       Impact factor: 3.402

6.  Oral human papillomavirus infection in men might contribute to HPV serology.

Authors:  S Syrjänen; T Waterboer; K Kero; J Rautava; K Syrjänen; S Grenman; M Pawlita
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-08-14       Impact factor: 3.267

Review 7.  Natural Acquired Immunity Against Subsequent Genital Human Papillomavirus Infection: A Systematic Review and Meta-analysis.

Authors:  Daniel C Beachler; Gwendolyne Jenkins; Mahboobeh Safaeian; Aimée R Kreimer; Nicolas Wentzensen
Journal:  J Infect Dis       Date:  2015-12-21       Impact factor: 5.226

8.  Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men.

Authors:  Beibei Lu; Raphael P Viscidi; Yougui Wu; Ji-Hyun Lee; Alan G Nyitray; Luisa L Villa; Eduardo Lazcano-Ponce; Roberto J Carvalho da Silva; Maria Luiza Baggio; Manuel Quiterio; Jorge Salmeron; Danelle C Smith; Martha E Abrahamsen; Mary R Papenfuss; Heather G Stockwell; Anna R Giuliano
Journal:  Cancer Res       Date:  2011-11-28       Impact factor: 12.701

9.  Human papillomavirus (HPV) 6, 11, 16, and 18 seroprevalence is associated with sexual practice and age: results from the multinational HPV Infection in Men Study (HIM Study).

Authors:  Beibei Lu; Raphael P Viscidi; Ji-Hyun Lee; Yougui Wu; Luisa L Villa; Eduardo Lazcano-Ponce; Roberto J Carvalho da Silva; Maria Luiza Baggio; Manuel Quiterio; Jorge Salmerón; Danelle C Smith; Martha Abrahamsen; Mary Papenfuss; Heather G Stockwell; Anna R Giuliano
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-03-04       Impact factor: 4.254

10.  Impact of Serum Antibodies to HPV Serotypes 6, 11, 16, and 18 to Risks of Subsequent Genital HPV Infections in Men: The HIM Study.

Authors:  Shitaldas J Pamnani; Staci L Sudenga; Raphael Viscidi; Dana E Rollison; B Nelson Torres; Donna J Ingles; Martha Abrahamsen; Luisa L Villa; Eduardo Lazcano-Ponce; Jorge Salmeron; Manuel Quiterio; Yangxin Huang; Amy Borenstein; Anna R Giuliano
Journal:  Cancer Res       Date:  2016-08-17       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.